Genetic or pharmacological blockage of CDX2-NUPR1 axis may strengthen the anticancer efficacy of adjuvant chemotherapy on stage II-III CDX2-positive colon cancer in vitro and in vivo. The gene discussed is CDX2; the disease is colonic neoplasm.